drugset / Trial / NCT00418756

Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects

NCT00418756

Phase 1 Completed 12 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects

Timeline

Start
2006-10
Primary completion
2006-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 400 mg Oral

Indications

No indication recorded.